http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-114074-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44e0905262f429c7590b40df8448c0c5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 |
| filingDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4ec157b01e24a12ff6eda7d4b29fde5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baf4e7b4d8ec5aa6ab1b2fed93b49a4e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bedff2266c1b1a34b7debb8f99b80849 |
| publicationDate | 2020-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-114074-A1 |
| titleOfInvention | PHARMACEUTICAL COMBINATION INCLUDING TRAMADOL HYDROCHLORIDE EXTENDED RELEASE AND IMMEDIATE RELEASE ETORICOXIB, AND ITS USE FOR THE TREATMENT OF PAIN |
| abstract | Pharmaceutical combination comprising: i) a first extended release tramadol hydrochloride formulation containing from 2.0% to 12.0% w / w tramadol hydrochloride, and ii) a second immediate release etoricoxib formulation containing from 6 , 0% to 18% w / w etoricoxib, solvents or vehicles; manufacturing process to prepare the pharmaceutical combination and the individual formulations, where the combination is presented in a single dosage such as capsules, tablets, bilayer tablets, granules and sachets. It further provides methods for preventing and treating pain, such as acute pain, and the use of the pharmaceutical combination for the prevention and treatment of pain, such as acute pain. Claim 1: A pharmaceutical combination characterized in that it comprises: a) a first extended release tramadol hydrochloride formulation containing 2.0% to 12.0% w / w of tramadol hydrochloride as the first pharmaceutically active ingredient, and 30% to 40 % w / w of pharmaceutically acceptable excipients; and b) a second immediate release etoricoxib formulation containing 6.0% to 18.0% w / w etoricoxib as the second pharmaceutically active ingredient, and 40% to 52% w / w pharmaceutically acceptable excipients, along with solvents. or pharmaceutically acceptable carriers; being the% w / w referred to the total weight of the combination, and where the solvents or vehicles are not included within the total weight of the same. Claim 21: An immediate release etoricoxib pharmaceutical formulation characterized by comprising: 10.3% to 31.0% w / w of etoricoxib, 13.8% to 21.2% w / w of meglumine, 5.4% a 8.6% w / w sodium carboxymethyl starch, 44.8 to 50.0% w / w microcrystalline cellulose, 1.4% to 4.3% w / w polyvinylpyrrolidone, 3.4% at 5, 2% w / w magnesium stearate, 0.2% to 0.4% w / w of a pharmaceutically acceptable dye, and ethanol and water as solvents or vehicles; the% w / w being referred to the total weight of the second immediate release formulation, and where the solvents or vehicles are not included within the total weight thereof. |
| priorityDate | 2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.